Arcutis Biotherapeutics Receives FDA Approval for Zoryve Topical Foam

by Warren Seah

Arcutis Biotherapeutics has recently announced that its Zoryve topical foam has received FDA approval for the treatment of seborrheic dermatitis. The company plans to make this innovative product widely available by the end of next month, offering new hope to individuals suffering from this condition. Following this news, shares of Arcutis Biotherapeutics surged by an impressive 31% to reach $3.19 after-hours.

Minerva Surgical to Delist Shares from Nasdaq

In an effort to streamline its operations and reduce expenses, Minerva Surgical has decided to delist its shares from the Nasdaq stock exchange. The last day of trading for Minerva Surgical shares is expected to be on or about December 28th. While this move may impact the company’s presence in the stock market, Minerva Surgical believes it will lead to a decrease in general and administrative expenses. As a result of this announcement, shares of Minerva Surgical dropped by 51% to $1.37 after-hours.

Enzo Biochem Sees Positive Revenue Growth in Q4

Enzo Biochem recently reported a 10% increase in revenue for the quarter ending on October 31st. This growth can be attributed to higher demand across multiple product areas. Additionally, Enzo Biochem managed to narrow its losses, with a decrease from $10.6 million, or 22 cents a share, to $6.6 million, or 13 cents a share, in comparison to the previous year. Following this positive news, shares of Enzo Biochem rose by 4.5% to $1.39 after-hours.

You may also like

Leave a Comment